| Ytd | -39.06% | |
| 1y | 13.64% |
| Open | 5.23 | Prev Close | 5.29 | Low | 5.21 | High | 5.41 | Mkt Cap | 324.99M |
| Vol | 273.42K | Avg Vol | 925.21K | EPS | -4.64 | P/E | N/A | Forward P/E | 23.40 |
| Beta | 0.64 | Short Ratio | 4.85 | Inst. Own | 78.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 5.56 | 200-d Avg | 6.55 | 1yr Est | 10.43 |
VNDA News
The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare hav
WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
NEREUS⢠Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. PR
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-s
B. Riley Securities analyst Madison El-Saadi reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA)
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Arrowstreet Capital Limited Partnership purchased a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:
Vanda Pharmaceuticals (NASDAQ: VNDA) reported second-quarter 2026 revenue of $50.5 million, down 4%
Vanda Pharmaceuticals NASDAQ: VNDA reported second-quarter 2026 revenue of $50.5 million, down 4% fr
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $1.04 per share versus the Zacks Cons
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(1.04) per share which missed the analyst c
Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2026 sales outlook from $240.000 million-$290.000 mill
Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%
Conference Call and Webcast to Follow WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceutical
This marks the first time the EMA has granted orphan drug designation recognition for a drug to trea
WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Adminis
WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today ann
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Japan's Ministry of Health
WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today ann
Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeli
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA)
WASHINGTON, May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today anno
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.82 per share versus the Zacks Cons
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that NEREUS™ (tradipitant) is now c
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today highlighted a legislative proposal contained
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the initiation of Thetis, a clinica
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a leader in innovative drug development and a voca
Top Wall Street analysts changed outlook on top names. See analyst ratings page for full view. EQIX
Truist Securities analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Adminis
Vanda stock climbs after the FDA approves Bysanti for bipolar disorder and schizophrenia and reviews
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Adminis
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Adminis
FDA's approval of Bysanti boosts Vanda's portfolio, with potential to treat bipolar disorder
Vanda shares rise after FDA approves Bysanti for bipolar I and schizophrenia, with launch planned fo
Editor’s Note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the he
VNDA: 54% | On Friday, The FDA Approved Vanda Pharmaceuticals' Bysanti (Milsaperidone) Tablets,
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA)
